66. IgA腎症 IgA nephropathy Clinical trials / Disease details
臨床試験数 : 275 / 薬物数 : 258 - (DrugBank : 82) / 標的遺伝子数 : 36 - 標的パスウェイ数 : 140
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT00498368 (ClinicalTrials.gov) | February 2009 | 9/7/2007 | Rituximab in Progressive Immunoglobulin A (IgA) Nephropathy | A Multicenter, Randomized, Prospective, Open-Label Trial of Rituximab in the Treatment of Progressive IgA Nephropathy | IgA Nephropathy | Drug: Intravenous Rituximab;Drug: ACE/ARB;Dietary Supplement: Omega-3 Fatty Acid Fish Oil Supplement | Mayo Clinic | Ohio State University;Stanford University;University of North Carolina, Chapel Hill;Columbia University;Genentech, Inc.;Biogen | Completed | 18 Years | 70 Years | All | 34 | Phase 4 | United States |
2 | NCT00549692 (ClinicalTrials.gov) | November 2007 | 25/10/2007 | Efficacy and Safety of Omega-3 Fatty Acids(Omacor®) for the Treatment of Immunoglobulin A Nephropathy | Minimization, Double-blind, Placebo-controlled, Multi-center, Phase 3 Study to Evaluate the Efficacy and Safety of Omega-3 Fatty Acids(Omacor®) for the Treatment of IgA Nephropathy | IgA Nephropathy | Drug: Omega-3 fatty acid ethylester90 | Kuhnil Pharmaceutical Co., Ltd. | Pronova BioPharma ASA | Completed | 18 Years | N/A | Both | 152 | Phase 3 | Korea, Republic of |